300750 Contemporary Amperex Technology (A)

DGAP-News: Armacell Group: Armacell H1 2019 Results

DGAP-News: Armacell Group / Key word(s): Half Year Results/Miscellaneous
Armacell Group: Armacell H1 2019 Results

02.09.2019 / 08:00
The issuer is solely responsible for the content of this announcement.


Press release

Armacell H1 2019 Results

  • Record net sales of EUR 321.8 million
  • Adjusted EBITDA of EUR 63.4 million, up by EUR 12.8 million
  • Adjusted EBITDA margin at 19.7%

Luxembourg, 2 September 2019 - Armacell, a global leader in flexible foam for the equipment insulation market and a leading provider of engineered foams, announced its H1 2019 results on 15 August 2019.

During the first six months of 2019, Armacell generated record net sales of EUR 321.8 million, up by 6.3% compared to the previous year's first half on a like-for-like basis (H1 2018: EUR 302.7 million). The net sales growth was mainly driven by volume growth in the Advanced Insulation business and by the fast-growing global PET business.

Adjusted EBITDA grew to EUR 63.4 million in H1 2019 (H1 2018: EUR 50.6 million). The adoption of IFRS 16 accounted for EUR 6.0 million for the first six months 2019. The adjusted EBITDA margin reached 19.7%.

Commenting on the company's financial performance, Patrick Mathieu, President & CEO of the Armacell Group, said: "Overall, our strategy is on track and we continue to generate a strong organic growth performance. The significant investments we made in the three regions we operate in and across both business divisions, Advanced Insulation and Engineered Foams, contributed positively to our results and will drive our business forward as we proceed through 2019."

In April 2019, Armacell and Thermaflex signed a commercial co-operation agreement to jointly serve the Russian market. As part of this agreement, the enlarged customer base will benefit from a combined elastomeric and thermoplastic product offering and enhanced customer service levels.

In H1 2019, Armacell continued to focus on the sales deployment and capacity expansion of ArmaGel - the company's next generation aerogel blanket technology - and PET foams. The latter was characterised by the development of additional PET production capacity in China to further strengthen Armacell's leadership in the APAC region.

Dr Max Padberg, CFO of the Armacell Group, commented: "In the first six months of the year, Armacell achieved a positive operating free cash flow and significantly reduced the net debt position to EUR 609 million (December 2018: EUR 623 million) and improved the leverage ratio to 5.4x (December 2018: 5.9x). Post IFRS 16, the net debt to EBITDA ratio equates to 5.1x."

Armacell is rated B (stable) by Standard & Poor's and B3 (stable) by Moody's.

-ends-

About Armacell
As the inventors of flexible foam for equipment insulation and a leading provider of engineered foams, Armacell develops innovative and safe thermal, acoustic and mechanical solutions that create sustainable value for its customers. Armacell's products significantly contribute to global energy efficiency making a difference around the world every day. With 3,100 employees and 24 production plants in 16 countries, the company operates two main businesses, Advanced Insulation and Engineered Foams, and generated net sales of EUR 610 million and adjusted EBITDA of EUR 106 million in 2018. Armacell focuses on insulation materials for technical equipment, high-performance foams for high-tech and lightweight applications and next generation aerogel blanket technology.

For more information, please visit:

Contacts

Corporate Investors
Tom Anen

Norman R. Rafael



02.09.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


866551  02.09.2019 

fncls.ssp?fn=show_t_gif&application_id=866551&application_name=news&site_id=research_pool
EN
02/09/2019

Underlying

300750Contemporary Amperex Technology (A)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Contemporary Amperex Technology (A)

 PRESS RELEASE

DGAP-News: ADL Bionatur Solutions Wins New Fermentation Client With Co...

DGAP-News: ADL Bionatur Solutions / Key word(s): Agreement ADL Bionatur Solutions Wins New Fermentation Client With Contract Revenues of EUR 20 Million 02.12.2019 / 09:06 The issuer is solely responsible for the content of this announcement. ADL BIONATUR SOLUTIONS WINS NEW FERMENTATION CLIENT WITH CONTRACT REVENUES OF EUR 20 MILLION The agreement with a leading Swiss biotech company includes technology transfer, upscaling and industrial-scale production of high value-added innovative ingredients for the cosmetics and nutrition industry ADL to apply its expertise in a...

 PRESS RELEASE

Admission of Security to Trading

NEX Exchange (NEXX) Admission of Security to Trading 02-Dec-2019 / 07:30 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. The following security will be admitted to trading on the NEX Exchange Growth Market with effect from 08:00, 02/12/2019. Name of Issuer: Dozens Savings Plc 5.00% Secured Bonds due 2 December 2020 ISIN: GB00BL1GTZ11  Symbol: DS04 EMS: 1 The Regulation Department NEX Exchange London Fruit & Wool Exchange 1 Duval Square London E1 6PW Tel: 020 7858 1655 Email:   W...

 PRESS RELEASE

Admission of Security to Trading

NEX Exchange (NEXX) Admission of Security to Trading 02-Dec-2019 / 07:30 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. The following security will be admitted to trading on the NEX Exchange Growth Market with effect from 08:00, 02/12/2019. Name of Issuer: SAPO PLC Ordinary Shares of GBP 0.01 ISIN: GB00B16GQJ90 Symbol: SAPO EMS: 5000 The Regulation Department NEX Exchange London Fruit & Wool Exchange 1 Duval Square London E1 6PW Tel: 020 7858 1655 Email:   Website: ...

 PRESS RELEASE

EQS-News: LIWET HOLDING AG publishes open letter to Dr. Martin Haefner...

EQS Group-News: Dynamics Group AG / Key word(s): Statement/Corporate Action LIWET HOLDING AG publishes open letter to Dr. Martin Haefner in various Swiss Sunday newspapers 01.12.2019 / 05:59 Open letter to Dr. Martin Haefner Dear Mr Haefner We share your concern about the future of Schmolz+Bickenbach (S+B). The company urgently needs money, everyone - including Liwet - agrees. However, there is still time to find a constructive solution for S+B that is in the interest of all, not only one particular shareholder. Liwet is ready to rescue the company and the 10,000 jobs. Liw...

 PRESS RELEASE

EQS-News: LIWET HOLDING AG publiziert offenen Brief an Dr. Martin Haef...

EQS Group-News: Dynamics Group AG / Schlagwort(e): Stellungnahme/Kapitalmaßnahme LIWET HOLDING AG publiziert offenen Brief an Dr. Martin Haefner in verschiedenen Schweizer Sonntagszeitungen 01.12.2019 / 05:59 Offener Brief an Dr. Martin Haefner Sehr geehrter Herr Haefner Wir teilen Ihre Sorge um die Zukunft von Schmolz+Bickenbach (S+B). Die Firma braucht dringend Geld; damit sind alle - auch Liwet - einverstanden. Noch bleibt Zeit, um eine konstruktive Lösung für S+B zu finden, die im Interesse aller Aktionäre ist, nicht nur eines einzigen. Liwet steht bereit, die Fir...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch